Jump to content

Oxycodone: Difference between revisions

From Pharmacopedia
[checked revision][checked revision]
← Older edit

MDElliottMD (talk | contribs)

3 user groups
5,189 edits
VisualWikitext
Pharmacopedia: remove contraindications parameter
parser-claude: Oxycodone MedTemplate refill, Top 300 stub upgrade
 
(3 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{MedTemplate
{{MedTemplate
| generic           = Oxycodone
| generic           = Oxycodone (hydrochloride)
| brand             = OxyContin
| brand             = OxyContin (ER), Roxicodone (IR), Oxaydo (IR abuse-deterrent), Xtampza ER (abuse-deterrent ER)
| structure         =  
| structure         =
| classes           = Opioid, Analgesic
| classes           = [[:Category:Opioid analgesics|Opioid analgesic (semi-synthetic)]], [[:Category:Schedule II controlled substances|Schedule II controlled substance]], [[:Category:Analgesics|Analgesic]]
| mechanism          = Mu-opioid receptor agonist
| uses              = <vote slug="moderate-severe-acute-pain-use">Moderate to severe acute pain (FDA)</vote>, <vote slug="post-surgical-pain-use">Postoperative pain (FDA)</vote>, <vote slug="cancer-pain-use">Cancer pain (FDA)</vote>, <vote slug="severe-chronic-pain-use">Severe chronic pain unresponsive to non-opioid alternatives (FDA, with the CDC opioid prescribing guidance constraints)</vote>
| uses              =  
| starting_dose    = IR opioid-naive: 5-10 mg PO every 4-6 hours as needed. ER opioid-naive: '''10 mg PO every 12 hours (lowest available)'''; titrate slowly to clinical effect
| starting_dose     =  
| preparations     = IR tablets 5, 7.5, 10, 15, 20, 30 mg; IR oral solution 5 mg/5 mL; concentrated solution 20 mg/mL; OxyContin ER tablets 10, 15, 20, 30, 40, 60, 80 mg; Xtampza ER capsules
| preparations      =  
| fda_max          = No fixed ceiling; titrate to clinical effect and tolerability with CDC opioid prescribing guidance constraints on morphine-milligram-equivalent (MME) totals
| fda_max           =  
| pill_id           =
| routes             =  
| routes           = Oral
| onset             =  
| onset             = 10-30 minutes (IR)
| duration           =  
| duration         = 4-6 hours (IR); 12 hours (ER)
| halflife           =
| halflife          = 3-5 hours (IR); 4.5 hours (ER)<ref name="oxycontin-label">FDA Prescribing Information, OxyContin (oxycodone hydrochloride extended-release), Purdue Pharma, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022272s033lbl.pdf</ref>
| bioavailability    =
| bioavailability   = ~60-87% (oral; high and more consistent than codeine or hydrocodone, making efficacy less CYP2D6-genotype-dependent)<ref name="oxycontin-label" />
| pregnancy         =  
| pregnancy        = Chronic third-trimester exposure produces neonatal opioid withdrawal syndrome and respiratory depression at delivery.{{citation needed}}
| legal              =  
| legal             = [[USLegal:Schedule II|Schedule II controlled substance]] in US<ref name="oxycontin-label" />
| intro              =
| mechanism         = <vote slug="oxycodone-mech-claim">Semi-synthetic μ-opioid receptor agonist, intermediate in potency between hydrocodone and morphine. Metabolized via CYP3A4 N-demethylation to noroxycodone (largely inactive) and via CYP2D6 O-demethylation to oxymorphone (active, more potent at μ). Unlike codeine and hydrocodone, oxycodone itself is largely the analgesic agent, so efficacy is less CYP2D6-genotype-dependent than for codeine.</vote> CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit juice) substantially raise plasma exposure. OxyContin's 2010 reformulation introduced an abuse-deterrent matrix that resists crushing and dissolution, a major harm-reduction intervention. CPIC provides CYP2D6 genotype-guided opioid selection guidance<ref name="cpic-opioid-cyp2d6">CPIC Guideline for CYP2D6, OPRM1, and COMT and Opioid Use, 2021. https://cpicpgx.org/guidelines/cpic-guideline-for-codeine-and-cyp2d6/</ref>.
| pharmacokinetics   =  
| pharmacodynamics  =  
| indications        =  
| dosing             =  
| effects            =  
| interactions      =
| pregnancy_details  =
| monitoring         =  
| counseling        =  
| anecdotes          =
| seealso            =
| references        =  
}}
}}


== References ==
<references />
[[Category:Opioid analgesics]]
[[Category:Schedule II controlled substances]]
[[Category:Analgesics]]
[[Category:Analgesics]]

Latest revision as of 06:37, 23 May 2026

Opioid analgesic (semi-synthetic), Schedule II controlled substance, Analgesic
Oxycodone (hydrochloride)
OxyContin (ER), Roxicodone (IR), Oxaydo (IR abuse-deterrent), Xtampza ER (abuse-deterrent ER)

Experience

👥 No personal reports yet
⚕ No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Classes
Opioid analgesic (semi-synthetic), Schedule II controlled substance, Analgesic
Pharmacy
Starting dose
IR opioid-naive: 5-10 mg PO every 4-6 hours as needed. ER opioid-naive: 10 mg PO every 12 hours (lowest available); titrate slowly to clinical effect
Preparations
IR tablets 5, 7.5, 10, 15, 20, 30 mg; IR oral solution 5 mg/5 mL; concentrated solution 20 mg/mL; OxyContin ER tablets 10, 15, 20, 30, 40, 60, 80 mg; Xtampza ER capsules
US FDA Max
No fixed ceiling; titrate to clinical effect and tolerability with CDC opioid prescribing guidance constraints on morphine-milligram-equivalent (MME) totals
Pharmacology
Routes
Oral
Onset
10-30 minutes (IR)
Duration
4-6 hours (IR); 12 hours (ER)
Half-life
3-5 hours (IR); 4.5 hours (ER)[2]
Bioavailability
~60-87% (oral; high and more consistent than codeine or hydrocodone, making efficacy less CYP2D6-genotype-dependent)[2]
Pregnancy
Chronic third-trimester exposure produces neonatal opioid withdrawal syndrome and respiratory depression at delivery.[citation needed]
Legal status
Schedule II controlled substance in US[2]
Purported mechanism
Semi-synthetic μ-opioid receptor agonist, intermediate in potency between hydrocodone and morphine. Metabolized via CYP3A4 N-demethylation to noroxycodone (largely inactive) and via CYP2D6 O-demethylation to oxymorphone (active, more potent at μ). Unlike codeine and hydrocodone, oxycodone itself is largely the analgesic agent, so efficacy is less CYP2D6-genotype-dependent than for codeine.0 CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit juice) substantially raise plasma exposure. OxyContin's 2010 reformulation introduced an abuse-deterrent matrix that resists crushing and dissolution, a major harm-reduction intervention. CPIC provides CYP2D6 genotype-guided opioid selection guidance[1].

References

  1. ↑ CPIC Guideline for CYP2D6, OPRM1, and COMT and Opioid Use, 2021. https://cpicpgx.org/guidelines/cpic-guideline-for-codeine-and-cyp2d6/
  2. ↑ 2.0 2.1 2.2 FDA Prescribing Information, OxyContin (oxycodone hydrochloride extended-release), Purdue Pharma, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022272s033lbl.pdf
Retrieved from "https://pharmacopedia.wiki/index.php?title=Oxycodone&oldid=6642"